Retinoic acid mediates regulation of network formation by coup-tfii and ve-cadherin expression by tgfβ receptor kinase in breast cancer cells

PLoS ONE

Volumn 5, Issue 4, 2010, Pages

  Prahalad, Priya ^a   Dakshanamurthy, Sivanesan ^a   Ressom, Habtom ^a   Byers, Stephen W ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALITRETINOIN; CHICKEN OVALBUMIN UPSTREAM PROMOTER TRANSCRIPTION FACTOR 2; MATRIGEL; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR KINASE; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CADHERIN; ANTINEOPLASTIC AGENT; CADHERIN; LEUKOCYTE ANTIGEN; RETINOIC ACID; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL FUSION; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIUM; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GENE SILENCING; GENOTYPE; MICROARRAY ANALYSIS; PROTEIN EXPRESSION; PROTEIN INDUCTION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; BREAST TUMOR; CELL DIFFERENTIATION; DRUG EFFECT; ENDOTHELIUM CELL; FEMALE; GENE REGULATORY NETWORK; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANTIGENS, CD; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CADHERINS; CELL DIFFERENTIATION; CELL FUSION; CELL LINE, TUMOR; COUP TRANSCRIPTION FACTOR II; ENDOTHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; TRETINOIN;

EID: 77956323587     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010023     Document Type: Article

References (47)

1. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186.
2. Kerbel R, Folkman J (2002) Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2: 727-739.
3. van der Schaft DW, Seftor RE, Seftor EA, Hess AR, Gruman LM, et al. (2004) Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. J Natl Cancer Inst 96: 1473-1477.
4. Hess AR, Seftor EA, Gruman LM, Kinch MS, Seftor RE, et al. (2006) VEcadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: implications for vasculogenic mimicry. Cancer Biol Ther 5: 228-233.
5. Hendrix MJ, Seftor EA, Kirschmann DA, Seftor RE (2000) Molecular biology of breast cancer metastasis. Molecular expression of vascular markers by aggressive breast cancer cells. Breast Cancer Res 2: 417-422.
6. Seftor EA, Meltzer PS, Schatteman GC, Gruman LM, Hess AR, et al. (2002) Expression of multiple molecular phenotypes by aggressive melanoma tumor cells: role in vasculogenic mimicry. Crit Rev Oncol Hematol 44: 17-27.
7. Shirakawa K, Kobayashi H, Heike Y, Kawamoto S, Brechbiel MW, et al. (2002) Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft. Cancer Res 62: 560-566.
8. Hendrix MJ, Seftor EA, Meltzer PS, Gardner LM, Hess AR, et al. (2001) Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc Natl Acad Sci U S A 98: 8018-8023.
9. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, et al. (1999) Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 155: 739-752.
10. Parker BS, Argani P, Cook BP, Liangfeng H, Chartrand SD, et al. (2004) Alterations in vascular gene expression in invasive breast carcinoma. Cancer Res 64: 7857-7866.
11. Shirakawa K, Furuhata S, Watanabe I, Hayase H, Shimizu A, et al. (2002) Induction of vasculogenesis in breast cancer models. Br J Cancer 87: 1454-1461.
12. Sharma N, Seftor RE, Seftor EA, Gruman LM, Heidger PM, Jr., et al. (2002) Prostatic tumor cell plasticity involves cooperative interactions of distinct phenotypic subpopulations: role in vasculogenic mimicry. Prostate 50: 189-201.
13. Sood AK, Fletcher MS, Coffin JE, Yang M, Seftor EA, et al. (2004) Functional role of matrix metalloproteinases in ovarian tumor cell plasticity. Am J Obstet Gynecol 190: 899-909.
14. Sun B, Zhang S, Zhao X, Zhang W, Hao X (2004) Vasculogenic mimicry is associated with poor survival in patients with mesothelial sarcomas and alveolar rhabdomyosarcomas. Int J Oncol 25: 1609-1614.
15. Fujimoto A, Onodera H, Mori A, Nagayama S, Yonenaga Y, et al. (2006) Tumour plasticity and extravascular circulation in ECV304 human bladder carcinoma cells. Anticancer Res 26: 59-69.
16. Sun B, Zhang S, Zhang D, Du J, Guo H, et al. (2006) Vasculogenic mimicry is associated with high tumor grade, invasion and metastasis, and short survival in patients with hepatocellular carcinoma. Oncol Rep 16: 693-698.
17. Yue WY, Chen ZP (2005) Does vasculogenic mimicry exist in astrocytoma? J Histochem Cytochem 53: 997-1002.
18. Hendrix MJ, Seftor EA, Hess AR, Seftor RE (2003) Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer 3: 411-421.
19. Endo M, Deonauth K, Prahalad P, Zhu J, Byers S (2008) Role of Sox-9, ER81, and VE-cadherin in Retinoic Acid-Mediated Trans-differentiation of Breast Cancer Cells. PLOS One.
20. Kruse SW, Suino-Powell K, Zhou XE, Kretschman JE, Reynolds R, et al. (2008) Identification of COUP-TFII orphan nuclear receptor as a retinoic acidactivated receptor. PLoS Biol 6: e227.
21. Nagasaki S, Suzuki T, Miki Y, Akahira J, Shibata H, et al. (2009) Chicken ovalbumin upstream promoter transcription factor II in human breast carcinoma: possible regulator of lymphangiogenesis via vascular endothelial growth factor-C expression. Cancer Sci 100: 639-645.
22. Swift MR, Weinstein BM (2009) Arterial-venous specification during development. Circ Res 104: 576-588.
23. Hofer E, Schweighofer B (2007) Signal transduction induced in endothelial cells by growth factor receptors involved in angiogenesis. Thromb Haemost 97: 355-363.
24. Eichmann A, Makinen T, Alitalo K (2005) Neural guidance molecules regulate vascular remodeling and vessel navigation. Genes Dev 19: 1013-1021.
25. You LR, Lin FJ, Lee CT, DeMayo FJ, Tsai MJ, et al. (2005) Suppression of Notch signalling by the COUP-TFII transcription factor regulates vein identity. Nature 435: 98-104.
26. Bombeli T, Mueller M, Haeberli A (1997) Anticoagulant properties of the vascular endothelium. Thromb Haemost 77: 408-423.
27. Camacho M, Rodriguez C, Salazar J, Martinez-Gonzalez J, Ribalta J, et al. (2008) Retinoic acid induces PGI synthase expression in human endothelial cells. J Lipid Res 49: 1707-1714.
28. Gifford SM, Grummer MA, Pierre SA, Austin JL, Zheng J, et al. (2004) Functional characterization of HUVEC-CS: Ca2+ signaling, ERK 1/2 activation, mitogenesis and vasodilator production. J Endocrinol 182: 485-499.
29. Faloon P, Arentson E, Kazarov A, Deng CX, Porcher C, et al. (2000) Basic fibroblast growth factor positively regulates hematopoietic development. Development 127: 1931-1941.
30. Flamme I, Risau W (1992) Induction of vasculogenesis and hematopoiesis in vitro. Development 116: 435-439
31. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, et al. (1996) Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380: 439-442.
32. Fong GH, Rossant J, Gertsenstein M, Breitman ML (1995) Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376: 66-70.
33. Shalaby F, Ho J, Stanford WL, Fischer KD, Schuh AC, et al. (1997) A requirement for Flk1 in primitive and definitive hematopoiesis and vasculogenesis. Cell 89: 981-990.
34. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, et al. (1995) Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376: 62-66.
35. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, et al. (1996) Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 87: 1161-1169.
36. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, et al. (1996) Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87: 1171-1180.
37. Vikkula M, Boon LM, Carraway KL, 3rd, Calvert JT, Diamonti AJ, et al. (1996) Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell 87: 1181-1190.
38. Esser S, Lampugnani MG, Corada M, Dejana E, Risau W (1998) Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. J Cell Sci 111(Pt13): 1853-1865.
39. Lindahl P, Johansson BR, Leveen P, Betsholtz C (1997) Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277: 242-245.
40. Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, et al. (2002) Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. Embo J 21: 1743-1753.
41. Nakagawa T, Li JH, Garcia G, Mu W, Piek E, et al. (2004) TGF-beta induces proangiogenic and antiangiogenic factors via parallel but distinct Smad pathways. Kidney Int 66: 605-613.
42. Cong R, Sun Q, Yang L, Gu H, Zeng Y, et al. (2009) Effect of Genistein on vasculogenic mimicry formation by human uveal melanoma cells. J Exp Clin Cancer Res 28: 124.
43. Yang Q, Sakurai T, Kakudo K (2002) Retinoid, retinoic acid receptor beta and breast cancer. Breast Cancer Res Treat 76: 167-173.
44. Hansen LA, Sigman CC, Andreola F, Ross SA, Kelloff GJ, et al. (2000) Retinoids in chemoprevention and differentiation therapy. Carcinogenesis 21: 1271-1279.
45. Zanetta L, Corada M, Grazia Lampugnani M, Zanetti A, Breviario F, et al. (2005) Downregulation of vascular endothelial-cadherin expression is associated with an increase in vascular tumor growth and hemorrhagic complications. Thromb Haemost 93: 1041-1046.
46. Piao M, Mori D, Satoh T, Sugita Y, Tokunaga O (2006) Inhibition of endothelial cell proliferation, in vitro angiogenesis, and the down-regulation of cell adhesion-related genes by genistein. Combined with a cDNA microarray analysis. Endothelium 13: 249-266.
47. Xu L, Bergan RC (2006) Genistein inhibits matrix metalloproteinase type 2 activation and prostate cancer cell invasion by blocking the transforming growth factor beta-mediated activation of mitogen-activated protein kinase-activated protein kinase 2-27-kDa heat shock protein pathway. Mol Pharmacol 70: 869-877.